# Fadi Fakhouri

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 61 papers | 4,542 citations | 29 h-index | 64 g-index |
| 64 ext. papers | 5,609 ext. citations | 8.3 avg, IF | 5.28 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 61 | Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. *Clinical Journal of the American Society of Nephrology: CJASN*, **2013**, 8, 554-62 | 6.9 | 426 |
| 60 | C3 glomerulopathy: consensus report. *Kidney International*, **2013**, 84, 1079-89 | 9.9 | 398 |
| 59 | Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. *Nature Genetics*, **2013**, 45, 531-6 | 36.3 | 357 |
| 58 | Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 859-67 | 12.7 | 320 |
| 57 | C3 glomerulopathy: a new classification. *Nature Reviews Nephrology*, **2010**, 6, 494-9 | 14.9 | 265 |
| 56 | Haemolytic uraemic syndrome. *Lancet, The*, **2017**, 390, 681-696 | 40 | 246 |
| 55 | Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. *Journal of Medical Genetics*, **2007**, 44, 193-9 | 5.8 | 223 |
| 54 | Collapsing glomerulopathy in a COVID-19 patient. *Kidney International*, **2020**, 98, 228-231 | 9.9 | 175 |
| 53 | Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. *American Journal of Kidney Diseases*, **2016**, 68, 84-93 | 7.4 | 162 |
| 52 | ANCA-negative pauci-immune renal vasculitis: histology and outcome. *Nephrology Dialysis Transplantation*, **2005**, 20, 1392-9 | 4.3 | 121 |
| 51 | Steroid-sensitive nephrotic syndrome: from childhood to adulthood. *American Journal of Kidney Diseases*, **2003**, 41, 550-7 | 7.4 | 120 |
| 50 | Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 50-59 | 6.9 | 106 |
| 49 | Hemolytic Uremic Syndrome in Pregnancy and Postpartum. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 1237-1247 | 6.9 | 104 |
| 48 | Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. *Journal of the American Society of Nephrology: JASN*, **2000**, 11, 1767-1775 | 12.7 | 103 |
| 47 | Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. *Blood*, **2008**, 112, 4542-5 | 2.2 | 98 |
| 46 | The expanding spectrum of renal diseases associated with antiphospholipid syndrome. *American Journal of Kidney Diseases*, **2003**, 41, 1205-11 | 7.4 | 76 |
| 45 | Eculizumab for treatment of rapidly progressive C3 glomerulopathy. *American Journal of Kidney Diseases*, **2015**, 65, 484-9 | 7.4 | 74 |

| | | | |
|---|---|---|---|
| 44 | Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. *Kidney International*, **2010**, 78, 279-86 | 9.9 | 67 |
| 43 | Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. *American Journal of Kidney Diseases*, **2014**, 63, 40-8 | 7.4 | 65 |
| 42 | Loss of DGKε induces endothelial cell activation and death independently of complement activation. *Blood*, **2015**, 125, 1038-46 | 2.2 | 63 |
| 41 | Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. *Kidney International*, **2018**, 94, 408-418 | 9.9 | 61 |
| 40 | Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. *American Journal of Kidney Diseases*, **2018**, 72, 84-92 | 7.4 | 55 |
| 39 | C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. *Kidney International*, **2017**, 92, 1232-1241 | 9.9 | 52 |
| 38 | Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?. *Nature Clinical Practice Nephrology*, **2007**, 3, 679-87 | | 45 |
| 37 | Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. *Journal of the American Society of Nephrology: JASN*, **2019**, 30, 2449-2463 | 12.7 | 42 |
| 36 | Etiology and Outcomes of Thrombotic Microangiopathies. *Clinical Journal of the American Society of Nephrology: CJASN*, **2019**, 14, 557-566 | 6.9 | 41 |
| 35 | Atypical and secondary hemolytic uremic syndromes have a distinct presentation and common genetic risk factors. *Kidney International*, **2019**, 95, 1443-1452 | 9.9 | 40 |
| 34 | Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome. *Kidney International Reports*, **2019**, 4, 434-446 | 4.1 | 33 |
| 33 | Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. *Blood*, **2020**, 136, 2103-2117 | 2.2 | 23 |
| 32 | Atypical HUS relapse triggered by COVID-19. *Kidney International*, **2021**, 99, 267-268 | 9.9 | 22 |
| 31 | Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. *Blood*, **2021**, 137, 2438-2449 | 2.2 | 21 |
| 30 | International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. *Autoimmunity Reviews*, **2017**, 16, 650-657 | 13.6 | 19 |
| 29 | Bronchiectasis is highly prevalent in anti-MPO ANCA-associated vasculitis and is associated with a distinct disease presentation. *Seminars in Arthritis and Rheumatism*, **2018**, 48, 70-76 | 5.3 | 19 |
| 28 | Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. *Haematologica*, **2019**, 104, 2501-2511 | 6.6 | 18 |
| 27 | Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. *Nature Reviews Nephrology*, **2021**, 17, 543-553 | 14.9 | 14 |

| | | | |
|---|---|---|---|
| 26 | Dampening of CD8+ T Cell Response by B Cell Depletion Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. *Arthritis and Rheumatology*, **2019**, 71, 641-650 | 9.5 | 14 |
| 25 | Heparin use during dialysis sessions induces an increase in the antiangiogenic factor soluble Flt1. *Nephrology Dialysis Transplantation*, **2014**, 29, 1225-31 | 4.3 | 13 |
| 24 | Mesangial IgG glomerulonephritis: a distinct type of primary glomerulonephritis. *Journal of the American Society of Nephrology: JASN*, **2002**, 13, 379-387 | 12.7 | 13 |
| 23 | Crystals from fat. Acute oxalate nephropathy. *Nephrology Dialysis Transplantation*, **2002**, 17, 1348-50 | 4.3 | 11 |
| 22 | Thrombotic microangiopathy: eculizumab for atypical haemolytic uraemic syndrome: what next?. *Nature Reviews Nephrology*, **2013**, 9, 495-6 | 14.9 | 10 |
| 21 | Translational implications of endothelial cell dysfunction in association with chronic allograft rejection. *Pediatric Nephrology*, **2016**, 31, 41-51 | 3.2 | 9 |
| 20 | Letter regarding "Minimal change disease relapse following SARS-CoV-2 mRNA vaccine". *Kidney International*, **2021**, 100, 458-459 | 9.9 | 9 |
| 19 | Antenatal corticosteroid therapy and COVID-19: Pathophysiological considerations. *Acta Obstetricia Et Gynecologica Scandinavica*, **2020**, 99, 952 | 3.8 | 8 |
| 18 | Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties. *Kidney International*, **2020**, 98, 1135-1148 | 9.9 | 8 |
| 17 | COVID-19 as a potential trigger of complement-mediated atypical HUS. *Blood*, **2021**, 138, 1777-1782 | 2.2 | 8 |
| 16 | Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. *Journal of Nephrology*, **2021**, 34, 1581-1590 | 4.8 | 7 |
| 15 | Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders. *Antibodies*, **2017**, 6, | 7 | 4 |
| 14 | The authors reply. *Kidney International*, **2020**, 98, 232 | 9.9 | 3 |
| 13 | C3 glomerulonephritis in a patient treated with anti-PD-1 antibody. *European Journal of Cancer*, **2020**, 125, 46-48 | 7.5 | 3 |
| 12 | Spectrum of Kidney Involvement in Patients with Myelodysplastic Syndromes. *Kidney International Reports*, **2021**, 6, 746-754 | 4.1 | 3 |
| 11 | Malignant hypertension and thrombotic microangiopathy: complement as a usual suspect. *Nephrology Dialysis Transplantation*, **2020**, | 4.3 | 2 |
| 10 | The man with "milk-shake" urine. *Lancet, The*, **2004**, 364, 1638 | 40 | 2 |
| 9 | Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome in solid organ transplant recipients. *Kidney International*, **2019**, 96, 1423-1424 | 9.9 | 2 |

| | | | |
|---|---|---|---|
| 8 | Urinary tract obstruction due to extramedullary plasmacytoma: report of two cases. *CKJ: Clinical Kidney Journal*, **2009**, 2, 143-6 | 4.5 | 1 |
| 7 | ANCA-Negative Pauci-Immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification. *American Journal of Kidney Diseases*, **2021**, | 7.4 | 1 |
| 6 | What is the impact of blood pressure on neurological symptoms and the risk of ESKD in primary and secondary thrombotic microangiopathies based on clinical presentation: a retrospective study.. *BMC Nephrology*, **2022**, 23, 39 | 2.7 | 0 |
| 5 | Eosinophilia Due to Central Venous Catheter in Hemodialysis Patients. *Kidney International Reports*, **2021**, 6, 1189-1191 | 4.1 | 0 |
| 4 | Infection in Patients with Suspected Thrombotic Microangiopathy Based on Clinical Presentation. *Clinical Journal of the American Society of Nephrology: CJASN*, **2021**, 16, 1355-1364 | 6.9 | 0 |
| 3 | The authors reply. *Kidney International*, **2019**, 96, 517-518 | 9.9 | |
| 2 | Prevalence and Factors Associated with Opioid Prescription in Swiss Chronic Hemodialysis Patients. *Kidney and Dialysis*, **2022**, 2, 6-15 | | |
| 1 | High levels of interleukine-6 in ascites prevent ascites reinfusion during hemodialysis. *Clinics and Research in Hepatology and Gastroenterology*, **2021**, 45, 101734 | 2.4 | |